



**The Drug Utilization Review (DUR) Board Reviewed
the Following New Drugs/Classes on
October 15, 2025**

Therapeutic Class	Drug Name	DURB Recommendation*
Hemophilia Treatments		
	<i>Alhemo (Subcutaneous) Solution</i>	NP/PA
	<i>Hypavzi (Subcutaneous) Solution</i>	P
	<i>Qfitlia (Subcutaneous) Solution</i>	NP/PA
Oncology, Oral - Other		
	<i>Romvimza (Oral) Capsules</i>	P/PA
	<i>Turalio (Oral) Capsules</i>	NP/PA
Colony Stimulating Factors		
	<i>Ryzneuta (Subcutaneous) Solution</i>	NP/PA (PDL and PADL)
Immunoglobulin A Nephropathy (IgAN) Agents		
	<i>Vanrafia (Oral) Tablet</i>	P/PA

*All recommendations apply to the PDL unless explicitly stated otherwise; DURB=Drug Utilization Review Board;
P=preferred; NP=non-preferred; PA=prior authorization; PDL=Preferred Drug List; PADL=Providers'
Administered Drug List